Does ACLARUBICIN Cause Second primary malignancy? 5 Reports in FDA Database
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
According to the FDA Adverse Event Reporting System (FAERS), 5 reports of Second primary malignancy have been filed in association with ACLARUBICIN. This represents 1.6% of all adverse event reports for ACLARUBICIN.
5
Reports of Second primary malignancy with ACLARUBICIN
1.6%
of all ACLARUBICIN reports
3
Deaths
1
Hospitalizations
How Dangerous Is Second primary malignancy From ACLARUBICIN?
Of the 5 reports, 3 (60.0%) resulted in death, 1 (20.0%) required hospitalization, and 1 (20.0%) were considered life-threatening.
Is Second primary malignancy Listed in the Official Label?
This adverse event is not currently listed in the official FDA drug label for ACLARUBICIN. However, 5 reports have been filed with the FAERS database.
What Other Side Effects Does ACLARUBICIN Cause?
Myelosuppression (80)
Bone marrow failure (73)
Off label use (38)
Nausea (35)
Infection (26)
Acute myeloid leukaemia (24)
Product use in unapproved indication (22)
Platelet count decreased (21)
Febrile neutropenia (19)
Pneumonia (19)
What Other Drugs Cause Second primary malignancy?
CYCLOPHOSPHAMIDE (1,247)
DOXORUBICIN (1,151)
VINCRISTINE (908)
IMATINIB (763)
PALBOCICLIB (658)
RITUXIMAB (646)
RUXOLITINIB (611)
ETOPOSIDE (573)
PREDNISONE (517)
OCTREOTIDE (496)
Which ACLARUBICIN Alternatives Have Lower Second primary malignancy Risk?
ACLARUBICIN vs ACLIDINIUM
ACLARUBICIN vs ACLIDINIUM\FORMOTEROL
ACLARUBICIN vs ACORAMIDIS
ACLARUBICIN vs ACTEMRA
ACLARUBICIN vs ACTIQ